Bioharvest Sciences vs Foghorn Therapeutics
Bioharvest Sciences and Foghorn Therapeutics are similar in size: $34.5m and $30.9m of revenue in their latest fiscal years. Bioharvest Sciences grew faster (37.0% against 36.8%). Bioharvest Sciences kept more of each dollar of sales as profit: a net margin of -32.3% against -240.3%.
| Latest fiscal year | Bioharvest SciencesBHST, 2025 | Foghorn TherapeuticsFHTX, 2025 |
|---|---|---|
| Revenue | $34.5m | $30.9m |
| Revenue growth | 37.0% | 36.8% |
| Net income | −$11.1m | −$74.3m |
| Operating margin | -16.2% | -279.5% |
| Net margin | -32.3% | -240.3% |
| Return on equity | -83.2% | — |
| Free cash flow | −$9.6m | −$86.1m |
| Cash | $23.0m | $80.9m |
| Total debt | $149,000 | $0 |
| Debt to equity | 0.6% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 106 |
| Market value | $34.7m | $124m |
| Price vs our value range | — | — |
| Moat score | — | 14 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 0 sales |